Skip to main content

Nystatin Ointment

Dosage form: ointment
Drug class: Topical antifungals

Medically reviewed by Last updated on Jan 1, 2021.

Nystatin Ointment Description

Nystatin is a polyene antifungal antibiotic drug obtained from Streptomyces nursei
Nystatin Ointment USP, for topical use only, contains 100,000 USP Nystatin Units per gram, in an ointment base of light mineral oil and white petrolatum. The structural formula is as follows:

Molecular Weight 926.13

Molecular Formula C47H75NO17

Nystatin Ointment - Clinical Pharmacology

Nystatin is not absorbed from intact skin or mucous membrane.

Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes.

Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing concentrations of nystatin, Candida albicans does not develop resistance to nystatin.Generally, resistance to nystatin does not develop during therapy. However, other species of 47 75 17 Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed.

Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.


Nystatin Ointment, is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species.
Nystatin Ointment is not indicated for systemic, oral, intravaginal or ophthalmic use.


Nystatin Ointment is contraindicated in patients with a history of hypersensitivity to any of their components.


Nystatin Ointment should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.

If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.


Patients using these medications should receive the following information and instructions :

1. The patient should be instructed to use these medications as directed (including the replacement of missed doses). These medications are not for any disorder other than that for which they are prescribed.

2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.

3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.

Laboratory Tests

If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.

Carcinogenisis, Mutagenisis, Impairment of Fertility

No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.

Pregnancy: Teratogenic Effects

Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

Nursing Mothers

It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

Pediatric use

Safety and effectiveness have been established in the pediatric population from birth to 16 years.


Adverse Reactions

The frequency of adverse events reported in patients using Nystatin Ointment preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application.
(SeePRECAUTIONS: General.)
To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc., at 1-888-943-3210 or 1-855-926-338 or FDA at 1-800-FDA-1088 (


Nystatin Ointment
Adults and Pediatric Patients (Neonates and Older):

Apply liberally to affected areas twice daily or as indicated until healing is complete.

How is Nystatin Ointment Supplied

Nystatin Ointment (100,000 USP Nystatin Units per gram) is a yellowish ointment available as follows:

NDC 33342-481-15 15 gram tube
NDC 33342-481-30 30 gram tube

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Manufactured for:
Macleods Pharma USA, Inc.

Princeton, NJ 08540

Macleods Pharmaceuticals Limited
At Oxalis Labs
Baddi, Himachal Pradesh, INDIA

Rev. 01/2021


Nystatin Ointment (100,000 USP Nystatin Units per gram)
Pack Count: 15 g Tube
NDC 33342-481-15

Nystatin Ointment (100,000 USP Nystatin Units per gram)
Pack Count: 15 g Carton
NDC 33342-481-15

Nystatin Ointment (100,000 USP Nystatin Units per gram)
Pack Count: 30 g Tube
NDC 33342-481-30

Nystatin Ointment (100,000 USP Nystatin Units per gram)
Pack Count: 30 g Carton
NDC 33342-481-30

Nystatin Ointment
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:33342-481
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Inactive Ingredients
Ingredient Name Strength
Product Characteristics
Color YELLOW Score
Shape Size
Flavor Imprint Code
# Item Code Package Description
1 NDC:33342-481-15 1 TUBE in 1 CARTON
1 15 g in 1 TUBE
2 NDC:33342-481-30 1 TUBE in 1 CARTON
2 30 g in 1 TUBE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA213826 01/29/2021
Labeler - Macleods Pharmaceuticals Limited (862128535)
Name Address ID/FEI Operations
OXALIS LABS 860120472 ANALYSIS(33342-481), LABEL(33342-481), MANUFACTURE(33342-481), PACK(33342-481)
Macleods Pharmaceuticals Limited